{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.03","spread":"0.03","upperLimit":"0.22","value":"0.080"},{"groupId":"OG001","lowerLimit":"0.03","spread":"0.03","upperLimit":"1","value":"0.135"},{"groupId":"OG002","lowerLimit":"0","spread":"0","upperLimit":"0.12","value":"0.080"},{"groupId":"OG003","lowerLimit":"0.01","spread":"0.01","upperLimit":"0.12","value":"0.050"}]}],"title":"Eribulin"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.07","spread":"0.07","upperLimit":"0.42","value":"0.250"},{"groupId":"OG001","lowerLimit":"0","spread":"0","upperLimit":"24","value":"0.305"},{"groupId":"OG002","lowerLimit":"0.03","spread":"0.03","upperLimit":"0.33","value":"0.300"},{"groupId":"OG003","lowerLimit":"0.13","spread":"0.13","upperLimit":"0.25","value":"0.170"}]}],"title":"Irinotecan"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.25","spread":"0.25","upperLimit":"1.03","value":"0.420"},{"groupId":"OG001","lowerLimit":"0","spread":"0","upperLimit":"24","value":"0.305"},{"groupId":"OG002","lowerLimit":"0.3","spread":"0.3","upperLimit":"0.53","value":"0.330"},{"groupId":"OG003","lowerLimit":"0.13","spread":"0.13","upperLimit":"0.55","value":"0.250"}]}],"title":"Active Metabolite SN-38"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"Participants received eribulin mesilate 1.4 mg/m\\^2 intravenous infusion on Days 1 and 8 and irinotecan hydrochloride 20 mg/m\\^2, intravenous infusion on Days 1 to 5 in every 21 days treatment cycle until disease progression, development of intolerable toxicity or withdrawal of consent.","id":"OG000","title":"Phase 1: Schedule A, Eribulin Mesilate 1.4 mg/m^2 + Irinotecan 20 mg/m^2"},{"description":"Participants received eribulin mesilate 1.4 mg/m\\^2, intravenous infusion on Days 1 and 8 and irinotecan hydrochloride 40 mg/m\\^2, intravenous infusion on Days 1 to 5 in every 21 days treatment cycle until disease progression, development of intolerable toxicity or withdrawal of consent.","id":"OG001","title":"Phase 1: Schedule A, Eribulin Mesilate 1.4 mg/m^2 + Irinotecan 40 mg/m^2"},{"description":"Participants received eribulin mesilate 1.4 mg/m\\^2 and irinotecan hydrochloride 100 mg/m\\^2 intravenous infusion on Days 1 and 8 in every 21 days treatment cycle until disease progression, development of intolerable toxicity or withdrawal of consent.","id":"OG002","title":"Phase 1: Schedule B, Eribulin Mesilate 1.4 mg/m^2 + Irinotecan 100 mg/m^2"},{"description":"Participants received eribulin mesilate 1.4 mg/m\\^2 and irinotecan hydrochloride 125 mg/m\\^2 intravenous infusion on Days 1 and 8 in every 21 days treatment cycle until disease progression, development of intolerable toxicity or withdrawal of consent.","id":"OG003","title":"Phase 1: Schedule B, Eribulin Mesilate 1.4 mg/m^2 + Irinotecan 125 mg/m^2"}],"paramType":"MEDIAN","populationDescription":"PK analysis set included participants who had documented dosing history and at least one post-dosing quantifiable drug concentration.","reportingStatus":"POSTED","timeFrame":"For eribulin, Cycle 1 Day 1: 0-120 hours post-eribulin infusion; For irinotecan and its metabolite, Cycle 1 Day 1: 0-24 hours post-irinotecan infusion (cycle length=21 days)","title":"Phase 1, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) of Eribulin, Irinotecan and Its Active Metabolite SN-38","type":"SECONDARY","unitOfMeasure":"hours"}